fbpx Who seeks pharmacotherapy for methamphetamine use in Australia? | NDARC - National Drug and Alcohol Research Centre

Who seeks pharmacotherapy for methamphetamine use in Australia?

Associate Professor Rebecca McKetin
Author: Associate Professor Rebecca McKetin

Resource Type: NDARC Seminars

Associate Professor Rebecca McKetin presented at the 2020 NDARC Webinar Series on Thursday, 21 May 2020.

This webinar describes participants in the N-ICE trial, a recently completed pharmacotherapy trial for methamphetamine dependence. The N-ICE trial is a randomised controlled trial of N-Acetyl Cysteine (NAC) for methamphetamine (“ice”) dependence. Through this recently completed trial we were able to recruit and follow-up a sizable cohort of people who wanted to reduce their methamphetamine use, many of whom had not previously received treatment, and the majority of whom smoked crystalline methamphetamine.

This webinar details the demographic and drug use characteristics of participants randomised into the trial, provides a taste of other trial data (including medication adherence data collected using eCAPTM technology), and discusses some of the challenges and successes in carrying out the trial.

Speaker Bio:
Associate Professor Rebecca McKetin, National Drug and Alcohol Research Centre, UNSW

A/Prof McKetin (BSc(Psychol)Hons. PhD) has a background in psychology and public health. She leads a program of research into stimulant use epidemiology and interventions at the National Drug and Alcohol Research Centre, University of New South Wales. She has published over 170 research articles in this area and her current work includes developing and trialling new treatment approaches for stimulant use, including online self-help and new medications. She led the recently completed N-ICE trial, the largest pharmacotherapy trial for methamphetamine use to have been conducted in Australia, which she will discuss in her presentation.